RxDoctor Payments Data

Bush Benjamin, MD

Internal Medicine · Frisco, TXNPI 1689171472

Payments from drug & device makers

$2,596in general payments, 2019–2025

Across 140 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$597
  • AbbVie$469
  • AstraZeneca$159
  • Boehringer Ingelheim$144
  • Itamar Medical Inc$131
  • GSK$130
  • plus $966 from 24 others

What the payments were for

  • Consulting fees$191%
  • Food & beverage$2,57799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,596 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$93,297
Medicare patients
210
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$53,877
TrulicityDulaglutide16$28,366
JardianceEmpagliflozin18$24,908
MounjaroTirzepatide13$17,937
JanuviaSitagliptin Phosphate19$17,825
FarxigaDapagliflozin Propanediol11$17,706
SynthroidLevothyroxine Sodium47$4,557
Atorvastatin Calcium204$1,723
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide39$1,641
Valsartan38$1,558
Levothyroxine Sodium155$1,462
Albuterol Sulfate HfaAlbuterol Sulfate34$1,339
UnithroidLevothyroxine Sodium38$1,310
Rosuvastatin Calcium104$1,211
Losartan Potassium98$1,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$597$53,87737 claims
Lilly USA, LLCTrulicity, Mounjaro$105$46,30329 claims
Boehringer IngelheimJardiance$144$24,90818 claims
MerckJanuvia$18$17,82519 claims
AstraZenecaFarxiga$159$17,70611 claims
AbbVieSynthroid$469$4,55747 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$114$2,772193 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →